As a follow-up to our recent announcement regarding the FDA approval of Zanabrutinib for the treatment of Waldenstrom's Macroglobulinemia (Sept 2, 2021), we are pleased to share this lecture, presented as a webinar on September 24, 2021 by Dr. Steven Treon.

In this presentation, Dr. Treon discusses the FDA approval of Zanabrutinib, as well as other investigational agents, including Venetoclax, Pirtobrutinib, Ulocuplumab, and Mavorixafor.


Feel free to visit our Bing Center YouTube channel for this and other informative videos covering many topics in the research & treatment of Waldenstrom's Macroglobulinemia.